Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 4,000,000 shares of common stock of PTC Therapeutics, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “PTCT.”

Based in Plainfield, New Jersey, PTC Therapeutics is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and counsel Yasin Keshvargar. The tax team included partner Lucy W. Farr. Partner Pritesh P. Shah provided intellectual property and technology advice. The environmental team included counsel Loyti Cheng and associate Michael Comstock. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post